Core Viewpoint - XORTX Therapeutics Inc. is advancing its late-stage clinical programs aimed at treating gout and progressive kidney disease, with a focus on innovative therapies for underserved conditions [2][4]. Group 1: Company Overview - XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company specializing in treatments for gout and progressive kidney disease [1][4]. - The company has three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury [4]. Group 2: Upcoming Events - XORTX is hosting a webinar on September 10, 2025, featuring Dr. Allen Davidoff, the CEO, who will discuss the company's mission and product pipeline [1][2]. - A live Q&A session will follow the presentation, allowing investors to engage directly with management [3]. Group 3: Product Pipeline and Market Opportunity - The lead program, XRx-026 (XORLO™), targets allopurinol-intolerant gout, with a New Drug Application (NDA) filing expected in the first half of 2026 [2]. - The market opportunity for XORLO™ is estimated at USD $700 million annually, with a diversified pipeline addressing multi-billion-dollar renal markets [2]. - Additional programs include XRx-008 for ADPKD, XRx-101 for acute kidney injury, and XRx-225 for Type 2 diabetic nephropathy [2][4].